Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhike Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Xinjiang Uygur Autonomous Region Institute of Drug Research, primarily indicated for the treatment of acute tracheobronchitis. The preparation is based on the classical Zhi Sou San formula, which consists of a synergistic blend of herbal ingredients including Platycodon grandiflorum, Schizonepeta tenuifolia, Aster tataricus, Stemona sessilifolia, Cynanchum stauntonii, Glycyrrhiza uralensis, and Citrus reticulata. It functions as an antitussive and expectorant, working to ventilate the lungs, resolve phlegm, and alleviate persistent coughing. The drug is widely manufactured and utilized in the Xinjiang region and is recognized for its efficacy in managing respiratory symptoms associated with bronchial infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhike Granules.